FDA Approves Onyda XR, First and Only Non-Stimulant Liquid Medication for ADHD
Clonidine hydrochloride (Onyda XR) is a once-daily extended-release oral suspension for the treatment of ADHD in pediatric patients 6 years of age and older. Clonidine hydrochloride may be used as monotherapy or as adjunct therapy to approved central nervous system stimulants.
Suicide is the second leading cause of death among college athletes
A study published in the British Journal of Sports Medicine found that suicide is the leading cause of death among NCAA athletes, and suicide rates more than doubled over the 20-year period studied.
Mental Health Awareness Month is observed every year in May. Image Credit: Katecat – stock.adobe.com
Psilocybin Treatment for PTSD Shows Positive Topline Results in Phase 2 Study
A single dose of Compass Pathways’ investigational drug, COMP360, was well tolerated and demonstrated durable improvements in CAPS-5 and SDS total scores compared to baseline.
Slideshow: Exercise may fight depression, mindfulness may help reduce drug use
The mental health crisis in the United States is worsening, and recent research is exploring new treatments and underlying causes.
Researchers Publish Positive Results on Efficacy of Long-Acting Subcutaneous Olanzapine
The drug, TEV-749, showed statistically significant and clinically meaningful efficacy results.
FDA approves oral treatment for postpartum depression
In August 2023, the FDA approved zuranolone (Zurzuvae) for the treatment of adults with postpartum depression (PPD). The drug is the first FDA-approved drug to treat postpartum depression in adults.
Read more: Mental and Behavioral Health Resource Center
Ready to take your pharmacy practice to the next level? Sign up now for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.
